Bicara Therapeutics Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing bifunctional therapies for solid tumors. Forms 8-K record financial results, business highlights, ficerafusp alfa clinical updates, material definitive agreements and other events, including common stock and pre-funded warrant financing.
The company’s proxy materials cover annual meeting proposals, board-class elections, auditor ratification and governance matters for an emerging growth company. The filings also describe capital-structure actions and formal exhibits tied to press releases, underwriting agreements and shareholder voting matters.
Ryan Cohlhepp reported sales of common stock of BCAX on Form 144.
The filing lists three reported sales: 12/15/2025 of 12,500 shares for $233,547.50; 01/15/2026 of 149 shares for $2,684.98; and 01/22/2026 of 3,828 shares for $69,295.99.
The excerpt also lists securities to be sold via exercise of stock options: 523 shares on 05/12/2024 and 3,108 shares on 02/25/2026.
Bicara Therapeutics is offering $150,000,000 of its common stock, subject to completion and the underwriters' 30-day option to purchase up to an additional $22,500,000 of shares.
The prospectus supplement states a reference market price of $16.40 per share as of February 23, 2026, and reports 54,612,477 shares outstanding as of September 30, 2025. As of December 31, 2025, Bicara reported approximately $414.8 million of cash, cash equivalents and investments.
Proceeds are intended to fund regulatory and commercial readiness and continued development and manufacturing of ficerafusp alfa, including Phase 2/3 and dosing-schedule work, and for general corporate purposes; the offering economics and net proceeds per share are shown in the prospectus supplement.
Bicara Therapeutics Inc. reported new preliminary Phase 1b data for its lead drug candidate ficerafusp alfa in first-line HPV-negative recurrent/metastatic head and neck squamous cell carcinoma, using a higher 2000mg every‑other‑week dose combined with pembrolizumab.
The 2000mg Q2W regimen showed a confirmed overall response rate of 48%, including 26% complete responses, and 77% of responders had deep responses with at least 80% tumor shrinkage. Safety was generally consistent with prior experience. Bicara plans to pursue a loading and every‑three‑week maintenance regimen, while its pivotal FORTIFI‑HN01 trial continues with a 1500mg weekly schedule, supported by Breakthrough Therapy Designation in this setting.
Vestal Point Capital and its chief investment officer, Ryan Wilder, disclosed a passive ownership stake in Bicara Therapeutics Inc. They report beneficial ownership of 3,575,000 shares of Bicara common stock, representing 6.5% of the class.
The percentage is based on 54,781,950 shares outstanding as of November 5, 2025, as cited from Bicara’s Form 10-Q. The shares are held through a Vestal Point fund and a managed account, which have the right to receive dividends and sale proceeds. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Bicara.
T. Rowe Price Investment Management, Inc. reported a passive ownership stake in Bicara Therapeutics Inc. common stock. The firm beneficially owns 3,236,595 shares, representing 5.9% of the outstanding common stock as of December 31, 2025.
T. Rowe Price has sole power to vote and dispose of these 3,236,595 shares and no shared voting or dispositive power. The firm certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Bicara Therapeutics.
Deep Track Capital and affiliated entities report a 5.02% passive stake in Bicara Therapeutics Inc. common stock. They beneficially own 2,750,000 shares of Bicara’s common stock, with shared power to vote and dispose of all such shares and no sole voting or dispositive power.
The reported ownership percentage is calculated using 54,781,850 shares outstanding as of November 5, 2025, as disclosed by Bicara. The filing is made on a Schedule 13G basis, and the filers certify that the shares were not acquired to change or influence control of the company.
FMR LLC has filed an amended ownership report showing beneficial ownership of 3,347,223 shares of Bicara Therapeutics Inc. common stock, representing 6.1% of the class as of December 31, 2025.
FMR reports sole voting power over 3,346,671 shares and sole dispositive power over 3,347,223 shares. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over 3,347,223 shares and no voting power. The filing notes that one or more other persons may have rights to dividends or sale proceeds, but no such person holds more than 5% of the outstanding common stock. The reporters certify the shares are not held to change or influence control of Bicara Therapeutics.
Bicara Therapeutics Inc. reported that President and COO, and director, Ryan Cohlhepp received a stock option award. The option gives him the right to buy 300,000 shares of common stock at an exercise price of $16.76 per share, granted on February 2, 2026.
The option expires on February 2, 2036 and vests in sixteen equal quarterly installments after February 2, 2026, as long as he continues serving the company on each vesting date. Following this grant, he beneficially owns 300,000 derivative securities directly.
Bicara Therapeutics Inc. reported that Chief Executive Officer and director Claire Mazumdar received a grant of stock options. On February 2, 2026, she was awarded options to purchase 450,000 shares of Bicara common stock at an exercise price of $16.76 per share.
The options vest in sixteen equal quarterly installments after February 2, 2026, and each vesting date requires her continued service with the company. Following this grant, she holds 450,000 stock options directly.
Bicara Therapeutics Inc. reported a new stock option grant to its Chief Medical Officer, David Raben. On February 2, 2026, he received a stock option covering 100,000 shares of common stock at an exercise price of $16.76 per share, expiring on February 2, 2036.
The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, and each installment requires his continued service on the vesting date. Following this grant, he beneficially owns 100,000 derivative securities directly.